Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 543960 | NSE Symbol : CONCORDBIO | ISIN : INE338H01029 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
24-Jan-2025	13-Feb-2025	Quarterly Results	Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and nine months period ended 31 December 2024. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the Third quarter and Nine months ended on December 31, 2024, along with the Limited Review Report with Unmodified Opinion issued by M/s. BSR & Co. LLP, the Statutory auditors. (As Per BSE Announcement Dated on: 13/02/2025)
06-Nov-2024	11-Nov-2024	Quarterly Results	Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2024 inter alia to consider and approve The Standalone and Consolidated Unaudited Financial Results for the Second quarter and half year ended September 30 2024 along with limited review report to be issued by the Statutory Auditors and to consider other business matters if any Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the Second quarter and half year ended September 30, 2024, along with the Limited Review Report with Unmodified Opinion issued by M/s. BSR & Co. LLP, the Statutory auditors. Read less.. (As Per BSE Announcement Dated on 11.11.2024)
31-Jul-2024	09-Aug-2024	Quarterly Results	Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve The Standalone and Consolidated Unaudited Financial Results for the first quarter ended June 30 2024 along with limited review report to be issued by the Statutory Auditors and to consider other business matters if any. With reference to the intimation of Board meeting submitted on July 31, 2024, we would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Friday, August 09, 2024, has inter-alia, approved Unaudited Standalone and Consolidated Financial Results for the First quarter ended on June 30, 2024. The said results were also reviewed by the Audit Committee of the Company in its meeting held on August 09, 2024. Unaudited Standalone and Consolidated Financial Statement for the first quarter ended june 30, 2024 (As Per BSE Announcement dated on 09.08.2024)
15-May-2024	23-May-2024	Dividend	Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2024 inter alia to consider and approve 1. Consider and approve the Standalone and Consolidated Audited Financial Results for the Fourth quarter and Year ended March 31 2024 2. To consider other business matters along with Recommendation of Dividend if any. 3. Any other Business Further in continuation of our earlier letter dated April 01 2024 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct to Regulate Monitor and Report trading by Designated Persons and their immediate relative the trading window for dealing in the securities of the Company shall remain closed up to 48 hours after the declaration of the Financial Results of the Company for the fourth quarter and Financial Year ended March 31 2024. You are requested to take the same on record. outcome of board meeting held today i.e Thursday may 23, 2024- audited finanical results for the quarter and financial year ended on march 31 2024 The Board of Directors ('the Board') as its meeting held on 23rd May, 2024 has recommended Dividend of Rs. 8.75 (@30%) per Equity Share of Face Value of Re. 1 Each Fully paid up for the Financial Year 2023-24, subject to approval by shareholders of the company at the ensuing AGM Due to typographical error the % was mentioned as 30% instead of 875% which is the correct figure (As Per BSE Announcement Dated on 23.05.2024)
30-Jan-2024	08-Feb-2024	Quarterly Results	Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results for the third quarter and Nine months ended December 31 2023 along with limited review report to be issued by the Statutory Auditors and to consider other business matters if any. Further in continuation of our earlier letter dated December 29 2023 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct to Regulate Monitor and Report trading by Designated Persons and their immediate relative the trading window for dealing in the securities of the Company shall remain closed up to 48 hours after the declaration of the Financial Results of the Company for the third quarter and Nine months ended December 31 2023. You are requested to take the same on record. with reference to the intimation of Board meeting submitted on January 30, 2024, we would like inform you that the Board of Directors of the company , at its meeting held today i.e. Thursday, February 08, 2024, has inter-alia approved unaudited standalone and consolidated financial results for the third quarter and nine months ended on December 31, 2023. Dear Sir/ Ma'am, With reference to the intimation of Board meeting submitted on January 30, 2024, we would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Thursday, February 08, 2024, has inter-alia, approved Unaudited Standalone and Consolidated Financial Results for the Third quarter and Nine months ended December 31, 2023. The said results were also reviewed by the Audit Committee of the Company in its meeting held on February 08, 2024. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the Third quarter and Nine months ended December 31, 2023, along with the Limited Review Report of the Statutory auditors (As Per BSE Announcement Dated on 08/02/2024)
25-Oct-2023	08-Nov-2023	Quarterly Results	Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve We hereby inform you that the meeting of the Board of Directors of the Company will be held on Wednesday November 08 2023 inter-alia to consider and approve the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended September 30 2023 along with limited review report to be issued by the Statutory Auditors and to consider other business matters if any. Further in continuation of our earlier letter dated September 22 2023 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct to Regulate Monitor and Report trading by Designated Persons and their immediate relative the trading window for dealing in the securities of the Company shall remain closed up to 48 hours after the declaration of the Financial Results of the Company for the quarter and half year ended 30 September 2023. we would like to inform you that the Board of Directors of the company at its meeting held today i.e. Wednesday, 08th November, 2023 has inter-alia approved unaudited standalone and consolidated financial results for the quarter and half year ended september 30, 2023. the said results were also reviewed by the audit committee of the company in its meeting held on 08th November, 2023 With reference to the intimation of Board meeting submitted on October 25, 2023, we would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Wednesday, November 08, 2023, has inter-alia, approved Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2023. The said results were also reviewed by the Audit Committee of the Company in its meeting held on November 08, 2023. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2023, along with the Limited Review Report of the Statutory auditors. The Board Meeting commenced at 11:00 AM and concluded at 03:00 P.M. (As Per BSE Announcement dated on 08.11.2023)
29-Aug-2023	06-Sep-2023	Quarterly Results	Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/09/2023 inter alia to consider and approve Accordingly pursuant to Clause J of Regulation 33 (3) of SEBI (Second amendment) Regulation 2023 which requires to submit financial results for the recent quarter within 21 days from the day of listing by the newly listed entity and Pursuant to provisions of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform that the meeting of the Board of Directors of the Company will be held on Wednesday 6th September 2023 inter-alia to consider and approve the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June 2023 along with limited review report to be issued by the Statutory Auditors and to consider other business matters if any. With reference to the intimation of Board meeting submitted on August 29, 2023, we would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Wednesday, September 06, 2023, has inter-alia, approved Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2023. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2023, along with the Limited Review Report of the Statutory auditors. The Board Meeting commenced at 2:30 PM and concluded at 3:30 PM. This is for your information and records. (As per BSE Announcement Dated on 06/09/2023)

LOGIN HERE

Concord Biotech Ltd

Board Meeting